↓ Skip to main content

Motavizumab for Prophylaxis of Respiratory Syncytial Virus in High-Risk Children: A Noninferiority Trial

Overview of attention for article published in Pediatrics, January 2010
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (84th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (56th percentile)

Citations

dimensions_citation
186 Dimensions

Readers on

mendeley
176 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Motavizumab for Prophylaxis of Respiratory Syncytial Virus in High-Risk Children: A Noninferiority Trial
Published in
Pediatrics, January 2010
DOI 10.1542/peds.2008-1036
Pubmed ID
Authors

Xavier Carbonell-Estrany, Eric A.F. Simões, Ron Dagan, Caroline B. Hall, Brian Harris, Micki Hultquist, Edward M. Connor, Genevieve A. Losonsky

Abstract

Palivizumab reduces respiratory syncytial virus (RSV) hospitalization in children at high risk by approximately 50% compared with placebo. We compared the efficacy and safety of motavizumab, an investigational monoclonal antibody with enhanced anti-RSV activity in preclinical studies, with palivizumab.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 176 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 1%
Israel 1 <1%
Egypt 1 <1%
United Kingdom 1 <1%
Japan 1 <1%
Spain 1 <1%
Unknown 169 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 34 19%
Student > Ph. D. Student 27 15%
Student > Master 19 11%
Student > Bachelor 18 10%
Other 11 6%
Other 35 20%
Unknown 32 18%
Readers by discipline Count As %
Medicine and Dentistry 67 38%
Agricultural and Biological Sciences 15 9%
Immunology and Microbiology 10 6%
Nursing and Health Professions 7 4%
Unspecified 7 4%
Other 24 14%
Unknown 46 26%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 July 2023.
All research outputs
#4,530,973
of 24,176,645 outputs
Outputs from Pediatrics
#7,964
of 17,677 outputs
Outputs of similar age
#25,103
of 170,553 outputs
Outputs of similar age from Pediatrics
#46
of 107 outputs
Altmetric has tracked 24,176,645 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 17,677 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 47.8. This one has gotten more attention than average, scoring higher than 53% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 170,553 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 107 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.